This HEAL Initiative grant seeks R61 applications for two-year exploratory/planning studies focused on initial non-addictive analgesic development. The primary goal is to enable future applications for the HEAL Initiative’s U19 Team Research grant. Awardees are expected to establish strong research teams, demonstrate feasibility, and gather preliminary data to support subsequent translational efforts. This limited-scope award supports team building, initial data collection, and recruiting collaborators. Proposals must detail a plan for developing a robust research team and a strategy for collecting preliminary data linking therapeutic targets to proposed pain indications, thereby laying groundwork for advanced analgesic development.
Opportunity ID: 334053
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-21-029 |
| Funding Opportunity Title: | HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.121 — Oral Diseases and Disorders Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 08, 2021 |
| Last Updated Date: | Jun 08, 2021 |
| Original Closing Date for Applications: | Oct 10, 2023 |
| Current Closing Date for Applications: | Oct 10, 2023 |
| Archive Date: | Nov 15, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments City or township governments Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities Independent school districts Private institutions of higher education Small businesses County governments Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Reissue of RFA-NS-21-016: The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed). Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The proposal must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-029.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 334053 Full Announcement-RFA-NS-21-029 -> RFA-NS-21-029-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00270600 | Nov 22, 2021 | Jan 24, 2023 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00267634 | Jun 19, 2021 | Jan 24, 2022 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278398 | Nov 14, 2022 | Oct 10, 2023 | View |
Package 1
Mandatory forms
334053 RR_SF424_5_0-5.0.pdf
334053 PHS398_CoverPageSupplement_5_0-5.0.pdf
334053 RR_OtherProjectInfo_1_4-1.4.pdf
334053 PerformanceSite_4_0-4.0.pdf
334053 RR_KeyPersonExpanded_4_0-4.0.pdf
334053 RR_Budget_3_0-3.0.pdf
334053 PHS398_ResearchPlan_4_0-4.0.pdf
334053 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
334053 RR_SubawardBudget30_3_0-3.0.pdf
334053 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
334053 RR_SF424_2_0-2.0.pdf
334053 PHS398_CoverPageSupplement_5_0-5.0.pdf
334053 RR_OtherProjectInfo_1_4-1.4.pdf
334053 PerformanceSite_2_0-2.0.pdf
334053 RR_KeyPersonExpanded_2_0-2.0.pdf
334053 RR_Budget_1_4-1.4.pdf
334053 PHS398_ResearchPlan_4_0-4.0.pdf
334053 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
334053 RR_SubawardBudget30_1_4-1.4.pdf
334053 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
334053 RR_SF424_5_0-5.0.pdf
334053 PHS398_CoverPageSupplement_5_0-5.0.pdf
334053 RR_OtherProjectInfo_1_4-1.4.pdf
334053 PerformanceSite_4_0-4.0.pdf
334053 RR_KeyPersonExpanded_4_0-4.0.pdf
334053 RR_Budget_3_0-3.0.pdf
334053 PHS398_ResearchPlan_5_0-5.0.pdf
334053 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
334053 RR_SubawardBudget30_3_0-3.0.pdf
334053 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
